• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度从禽类中分离出的高致病性 H5N1 流感病毒对神经氨酸酶抑制剂的敏感性特征。(2006-2015 年)

Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).

机构信息

ICAR- National Institute of High Security Animal Diseases, Anand Nagar, Bhopal 462022, Madhya Pradesh, India.

ICAR- National Institute of High Security Animal Diseases, Anand Nagar, Bhopal 462022, Madhya Pradesh, India.

出版信息

Antiviral Res. 2018 Oct;158:143-146. doi: 10.1016/j.antiviral.2018.08.007. Epub 2018 Aug 17.

DOI:10.1016/j.antiviral.2018.08.007
PMID:30125616
Abstract

We tested 65 highly pathogenic avian influenza (HPAI) A(H5N1) viruses, isolated from avian species in India between 2006 and 2015, for susceptibility to the FDA approved neuraminidase (NA) inhibitors (NAIs), oseltamivir and zanamivir using a phenotypic fluorescence-based assay. The overall incidence of resistant variants among HPAI A(H5N1) viruses was 7.69% (5/65). The NA inhibition assay identified 3 viruses resistant to oseltamivir (N294S substitution, N2 numbering) and 2 cross-resistant to oseltamivir and zanamivir (E119A or I117V+E119A substitutions), all of which belonged to hemagglutinin (HA) clade 2.2 (5/17) and predominantly circulated in Indian poultry during 2006-2010. In comparison to E119A substitution alone, viruses with I117V+E119A double substitutions showed greater reduction in susceptibility to both oseltamivir and zanamivir. The NAI resistance-associated NA markers, identified in this study, were as a result of naturally occurring mutations. Of note, 48 viruses of HA clade 2.3.2.1 that circulated in Indian poultry during 2011-2015 were susceptible to both oseltamivir and zanamivir. It is essential to monitor NAI susceptibility among human and avian HPAI A(H5N1) viruses that would provide baseline data to develop strategies for pandemic preparedness and therapeutic interventions.

摘要

我们测试了 65 株 2006 年至 2015 年期间在印度从禽类分离的高致病性禽流感(HPAI)A(H5N1)病毒,使用基于荧光的表型测定法对其对美国食品和药物管理局批准的神经氨酸酶(NA)抑制剂(NAI),奥司他韦和扎那米韦的敏感性。HPAI A(H5N1)病毒中耐药变异株的总体发生率为 7.69%(5/65)。NA 抑制测定法鉴定出 3 株对奥司他韦耐药的病毒(N294S 取代,N2 编号)和 2 株对奥司他韦和扎那米韦交叉耐药的病毒(E119A 或 I117V+E119A 取代),均属于血凝素(HA) 2.2 分支(5/17),主要在 2006 年至 2010 年期间在印度家禽中流行。与单独的 E119A 取代相比,具有 I117V+E119A 双取代的病毒对奥司他韦和扎那米韦的敏感性降低更大。本研究中鉴定的 NAI 耐药相关 NA 标记是由于自然发生的突变。值得注意的是,2011 年至 2015 年在印度家禽中流行的 HA 2.3.2.1 分支的 48 株病毒对奥司他韦和扎那米韦均敏感。监测人类和禽类 HPAI A(H5N1)病毒对 NAI 的敏感性非常重要,这将为制定大流行准备和治疗干预策略提供基线数据。

相似文献

1
Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).印度从禽类中分离出的高致病性 H5N1 流感病毒对神经氨酸酶抑制剂的敏感性特征。(2006-2015 年)
Antiviral Res. 2018 Oct;158:143-146. doi: 10.1016/j.antiviral.2018.08.007. Epub 2018 Aug 17.
2
A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.神经氨酸酶中 I117T 取代导致高致病性禽流感 H5N1 病毒对奥司他韦和扎那米韦的敏感性降低。
Vet Microbiol. 2019 Aug;235:21-24. doi: 10.1016/j.vetmic.2019.06.005. Epub 2019 Jun 5.
3
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.对可能对多种神经氨酸酶抑制剂具有耐药性的流感病毒 N1 株进行分析和鉴定。
J Virol. 2015 Jan;89(1):287-99. doi: 10.1128/JVI.02485-14. Epub 2014 Oct 15.
4
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.对N4、N5、N6和N8神经氨酸酶亚型禽流感病毒中的神经氨酸酶抑制剂耐药性标志物进行筛查。
J Virol. 2017 Dec 14;92(1). doi: 10.1128/JVI.01580-17. Print 2018 Jan 1.
5
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.神经氨酸酶抑制剂耐药突变对 clade 2.2 A/土耳其/15/06(H5N1)流感病毒在雪貂中的致病性的影响。
PLoS Pathog. 2010 May 27;6(5):e1000933. doi: 10.1371/journal.ppat.1000933.
6
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.新兴甲型流感病毒对神经氨酸酶和帽子依赖性内切酶抑制剂的基因型和表型敏感性。
Antiviral Res. 2024 Sep;229:105959. doi: 10.1016/j.antiviral.2024.105959. Epub 2024 Jul 8.
7
Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.2002-2012 年全球分离的高致病性流感 A(H5N1)病毒的抗病毒耐药性表明需要持续监测。
Antiviral Res. 2013 May;98(2):297-304. doi: 10.1016/j.antiviral.2013.02.013. Epub 2013 Feb 28.
8
Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.鉴定出具有 N294S 和 S246N 神经氨酸酶替换的印度尼西亚 2.1 分支高致病性 H5N1 流感病毒,这进一步降低了奥司他韦的敏感性。
Antiviral Res. 2018 May;153:95-100. doi: 10.1016/j.antiviral.2018.03.007. Epub 2018 Mar 21.
9
Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.在人气道上皮细胞共感染模型中具有神经氨酸酶抑制剂抗性替代的乙型流感病毒的竞争适应性
J Virol. 2015 Apr;89(8):4575-87. doi: 10.1128/JVI.02473-14. Epub 2015 Feb 11.
10
Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.类人受体特异性不影响H5N1流感病毒对神经氨酸酶抑制剂的敏感性。
PLoS Pathog. 2008 Apr 11;4(4):e1000043. doi: 10.1371/journal.ppat.1000043.

引用本文的文献

1
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.2022 年美国从鸟类和哺乳动物中分离出的 2.3.4.4b 分支高致病性禽流感 A(H5N1)病毒的抗病毒敏感性。
Antiviral Res. 2023 Sep;217:105679. doi: 10.1016/j.antiviral.2023.105679. Epub 2023 Jul 24.
2
Assessing the susceptibility of highly pathogenic avian influenza H5N1 viruses to oseltamivir using embryonated chicken eggs.用鸡胚评估高致病性禽流感 H5N1 病毒对奥司他韦的敏感性。
Indian J Med Res. 2019 Nov;150(5):486-491. doi: 10.4103/ijmr.IJMR_845_18.